- Home
- ATXS vs NXXT Comparison
ATXS vs NXXT Comparison
Compare ATXS & NXXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- NXXT
- Stock Information
- Founded
- ATXS 2008
- NXXT 2019
- Country
- ATXS United States
- NXXT United States
- Employees
- ATXS N/A
- NXXT N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- NXXT
- Sector
- ATXS Health Care
- NXXT
- Exchange
- ATXS Nasdaq
- NXXT NYSE
- Market Cap
- ATXS 401.2M
- NXXT 326.6M
- IPO Year
- ATXS 2015
- NXXT N/A
- Fundamental
- Price
- ATXS $6.65
- NXXT $1.67
- Analyst Decision
- ATXS Strong Buy
- NXXT Strong Buy
- Analyst Count
- ATXS 7
- NXXT 1
- Target Price
- ATXS $32.43
- NXXT $6.00
- AVG Volume (30 Days)
- ATXS 304.1K
- NXXT 245.4K
- Earning Date
- ATXS 08-11-2025
- NXXT 08-14-2025
- Dividend Yield
- ATXS N/A
- NXXT N/A
- EPS Growth
- ATXS N/A
- NXXT N/A
- EPS
- ATXS N/A
- NXXT N/A
- Revenue
- ATXS N/A
- NXXT $37,445,833.00
- Revenue This Year
- ATXS N/A
- NXXT $193.84
- Revenue Next Year
- ATXS N/A
- NXXT N/A
- P/E Ratio
- ATXS N/A
- NXXT N/A
- Revenue Growth
- ATXS N/A
- NXXT 52.33
- 52 Week Low
- ATXS $3.56
- NXXT $1.59
- 52 Week High
- ATXS $12.92
- NXXT $5.00
- Technical
- Relative Strength Index (RSI)
- ATXS 60.88
- NXXT N/A
- Support Level
- ATXS $5.94
- NXXT N/A
- Resistance Level
- ATXS $6.49
- NXXT N/A
- Average True Range (ATR)
- ATXS 0.34
- NXXT 0.00
- MACD
- ATXS -0.00
- NXXT 0.00
- Stochastic Oscillator
- ATXS 74.74
- NXXT 0.00
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About NXXT NEXTNRG INC
NextNRG Inc is engaged in developing an integrated ecosystem that combines solar energy generation, battery storage, smart microgrids, wireless electric vehicle (EV) charging, and on-demand fuel delivery. The company is also focused on combining renewable energy innovation with mobile fueling expertise to build a sustainable energy ecosystem that bridges traditional fuel needs with AI-powered clean energy solutions.